Research · Source update
Foundayo trial analysis examines older adults
Source context: Read the linked original research or registry entry for study status and limitations.
Lilly reported a subgroup analysis of ATTAIN trials among adults aged 65 years and older. MyDosePro reviewed the originating organization's statement to identify the reported results and their limitations.
What prompted this update?
Lilly reported a subgroup analysis of ATTAIN trials among adults aged 65 years and older. MyDosePro reviewed the originating organization's statement to identify the reported results and their limitations. The originating source is Lilly ATTAIN older-adult subgroup analysis, dated 2026-05-22.
What did the source report?
In ATTAIN-1, the highest studied dose was associated with a 13% average weight reduction among older participants. The sponsor reported a 13% mean reduction at the highest analyzed dose in participants aged at least 65 in the ATTAIN-1 analysis.
How should the results be interpreted?
Subgroup findings can be informative but do not establish a separate benefit for every older adult or replace a geriatric safety assessment. An age subgroup is not a new randomized trial, and effects on lean mass, strength and hydration require attention in older adults.
What remains uncertain?
These findings apply to the specific study, date, population, product and endpoint described in the primary source. The source may be a sponsor announcement before full peer-reviewed publication. Check the original document and current regulatory status before drawing conclusions about personal treatment. Where a study or subgroup result was first released by a manufacturer, it should not be treated as independent confirmation of every claim; compare the full protocol, population, endpoints and subsequent publications.
What does this mean for patients?
Age-specific treatment decisions still weigh tolerability and function. Treatment decisions depend on approved labeling, individual medical circumstances, availability and actual insurance benefits. MyDosePro offers educational context, not individualized prescribing or coverage confirmation.
The bottom line
Age-specific treatment decisions still weigh tolerability and function.
Written and published by MyDosePro as an educational explanation of publicly available evidence. The linked primary source is dated 2026-05-22. We identify trial registrations separately from published results and do not provide individual prescribing advice.
Primary sourceLilly ATTAIN older-adult subgroup analysis ↗
Source event or update: 2026-05-22. Our interpretation is educational and does not replace medical or insurance advice.